Success Metrics

Clinical Success Rate

100.0%

Based on 2 completed trials

Completion Rate

100%(2/2)

Active Trials

1(25%)

Results Posted

50%(1 trials)

Phase Distribution

Ph phase_2

75%

Ph phase_1

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

1(25.0%)

Phase 2Efficacy & side effects

3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(2)

Terminated(1)

Detailed Status

Completed2

Withdrawn1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 11 (25.0%)

Phase 23 (75.0%)

Trials by Status

completed250%

withdrawn125%

active_not_recruiting125%

Recent Activity

1 active trials

Showing 4 of 4

completedphase_2

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

NCT03625323

completedphase_2

Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

NCT04811027

active_not_recruitingphase_2

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy

NCT05747794

withdrawnphase_1

A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel

NCT04252768

Clinical Trials (4)

Showing 4 of 4 trials

NCT03625323Phase 2

Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

Completed

NCT04811027Phase 2

Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC

Completed

NCT05747794Phase 2

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination with Paclitaxel Chemotherapy

Active Not Recruiting

NCT04252768Phase 1

A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4